{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:35:01Z","timestamp":1793313301169,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,12,17]],"date-time":"2008-12-17T00:00:00Z","timestamp":1229472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1007\/s11606-008-0866-8","type":"journal-article","created":{"date-parts":[[2008,12,16]],"date-time":"2008-12-16T14:35:25Z","timestamp":1229438125000},"page":"226-232","source":"Crossref","is-referenced-by-count":104,"title":["Home Buprenorphine\/Naloxone Induction in Primary Care"],"prefix":"10.1007","volume":"24","author":[{"given":"Joshua D.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danae","family":"DiRocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc N.","family":"Gourevitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,12,17]]},"reference":[{"key":"866_CR1","volume-title":"Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: A Treatment Improvement Protocol (TIP) Series 40","author":"Center for Substance Abuse Treatment","year":"2004","unstructured":"Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: A Treatment Improvement Protocol (TIP) Series 40. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004."},{"issue":"7","key":"866_CR2","first-page":"1025","volume":"151","author":"EC Strain","year":"2004","unstructured":"Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opiate dependence. Am J Psychiatry. 2004;151(7):1025\u201330.","journal-title":"Am J Psychiatry"},{"issue":"18","key":"866_CR3","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","volume":"343","author":"RE Johnson","year":"2000","unstructured":"Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. N Engl J Med. 2000;343(18):1290\u20137.","journal-title":"N Engl J Med"},{"issue":"2","key":"866_CR4","first-page":"CD002207","volume":"16","author":"R Mattick","year":"2008","unstructured":"Mattick R, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;16(2):CD002207.","journal-title":"Cochrane Database Syst Rev"},{"key":"866_CR5","unstructured":"Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. SAMHSA Evaluation of the Impact of the DATA Waiver Program. http:\/\/buprenorphine.samsha.gov\/ , accessed May 12, 2008."},{"issue":"7","key":"866_CR6","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/jama.294.7.784","volume":"294","author":"B Kuehn","year":"2005","unstructured":"Kuehn B. Office-based treatment of opioid addiction achieving goals. JAMA. 2005;294(7):784\u20136.","journal-title":"JAMA"},{"issue":"1","key":"866_CR7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.drugalcdep.2004.12.008","volume":"79","author":"LE Sullivan","year":"2005","unstructured":"Sullivan LE, Chawarski M, O\u2019Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend. 2005;79(1):113\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"866_CR8","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s11606-008-0686-x","volume":"23","author":"AY Walley","year":"2008","unstructured":"Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393\u20138.","journal-title":"J Gen Intern Med"},{"issue":"9","key":"866_CR9","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s11606-007-0264-7","volume":"22","author":"CO Cunningham","year":"2007","unstructured":"Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22(9):1325\u20139.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"866_CR10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1300\/J069v25n04_09","volume":"25","author":"W Kissin","year":"2006","unstructured":"Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25(4):91\u2013103.","journal-title":"J Addict Dis"},{"key":"866_CR11","unstructured":"Netherland J, Botsko M, Egan J, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. In Press, available online 20 Aug 2008."},{"key":"866_CR12","unstructured":"American Academy of Addiction Psychiatry. Buprenorphine in the treatment of opioid dependence. http:\/\/training.aaap.org\/ , accessed Nov. 14, 2008."},{"key":"866_CR13","unstructured":"American Society of Addiction Medicine, Clinical Tools, Inc. Online buprenorphine training. http:\/\/buprenorphineCME.com , accessed Nov. 14, 2008."},{"issue":"2","key":"866_CR14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jsat.2004.06.005","volume":"27","author":"DA Fiellin","year":"2004","unstructured":"Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004;27(2):153\u20139.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"866_CR15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1370\/afm.665","volume":"5","author":"IL Mintzer","year":"2007","unstructured":"Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med. 2007;5(2):146\u201350.","journal-title":"Ann Fam Med"},{"issue":"2","key":"866_CR16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11606-006-0023-1","volume":"22","author":"DP Alford","year":"2007","unstructured":"Alford DP, LaBelle CT, Richardson JM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. 2007;22(2):171\u20136.","journal-title":"J Gen Intern Med"},{"issue":"8","key":"866_CR17","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/j.1525-1497.2006.00544.x","volume":"21","author":"MK Paasche-Orlow","year":"2006","unstructured":"Paasche-Orlow MK, Schillinger D, Greene SM, Wagner EH. How health care systems can begin to address the challenge of limited literacy. J Gen Intern Med. 2006;21(8):884\u20137.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"866_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0376-8716(90)90078-S","volume":"26","author":"WR Lange","year":"1990","unstructured":"Lange WR, Fudala PJ, Dax EM, Johnson RE. Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alc Dep. 1990;26(1):19\u201328.","journal-title":"Drug Alc Dep"},{"issue":"20","key":"866_CR19","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","volume":"267","author":"RE Johnson","year":"1992","unstructured":"Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine for opioid dependence. JAMA. 1992;267(20):2750\u20135.","journal-title":"JAMA"},{"issue":"4","key":"866_CR20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","volume":"93","author":"W Ling","year":"1998","unstructured":"Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93(4):475\u201386.","journal-title":"Addiction"},{"issue":"S1","key":"866_CR21","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1080\/10550490490440807","volume":"13","author":"L Amass","year":"2004","unstructured":"Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict. 2004;13(S1):S42\u201366.","journal-title":"Am J Addict"},{"issue":"11","key":"866_CR22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1525-1497.2005.0228.x","volume":"20","author":"MD Stein","year":"2005","unstructured":"Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20(11):1038\u201341.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"866_CR23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/ADM.0b013e31809b5df2","volume":"1","author":"JW Finch","year":"2007","unstructured":"Finch JW, Kamien JB, Amass L. Two-year experience with buprenorphine-naloxone (Suboxone) for maintenance treatment of opioid dependence within a private practice setting. J Addict Med. 2007;1(2):104\u201310.","journal-title":"J Addict Med"},{"issue":"7","key":"866_CR24","first-page":"500","volume":"40","author":"C Cunningham","year":"2008","unstructured":"Cunningham C, Giovanniello A, Sacajiu G, et al. Buprenorphine treatment in an urban community health center: what to expect. Fam Med. 2008;40(7):500\u20136.","journal-title":"Fam Med"},{"key":"866_CR25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-3565(25)10510-7","volume":"274","author":"SL Walsh","year":"1995","unstructured":"Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther. 1995;274:361\u201372.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2 Suppl","key":"866_CR26","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","volume":"70","author":"RE Johnson","year":"2003","unstructured":"Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70(2 Suppl):S59\u201377.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"866_CR27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1300\/J069v26n02_03","volume":"26","author":"S Magura","year":"2007","unstructured":"Magura S, Lee S, Salsitz E, et al. Outcomes of buprenorphine maintenance in office-based practice. J Addict Dis. 2007;26(2):13\u201323.","journal-title":"J Addict Dis"},{"issue":"5","key":"866_CR28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1017\/S146114570700836X","volume":"11","author":"M Soyka","year":"2008","unstructured":"Soyka M, Zingg C, Koler G, Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol. 2008;11(5):641\u201353.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"866_CR29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","volume":"355","author":"DA Fiellin","year":"2006","unstructured":"Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365\u201374.","journal-title":"N Engl J Med"},{"issue":"2","key":"866_CR30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1176\/appi.ajp.162.2.340","volume":"162","author":"RS Schottenfeld","year":"2005","unstructured":"Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psych. 2005;162(2):340\u20139.","journal-title":"Am J Psych"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-008-0866-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-008-0866-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-008-0866-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T06:12:32Z","timestamp":1738822352000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-008-0866-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,17]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["866"],"URL":"https:\/\/doi.org\/10.1007\/s11606-008-0866-8","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,17]]}}}